More Research on Potency, Efficacy of TILs Is Needed in Melanoma

Source: Targeted Oncology, July 2021

Despite questions about the potency and efficacy of tumor-infiltrating lymphocytes (TILs), ongoing research into their curative potential, especially in metastatic melanoma, continues to excite investigators. Inge Marie Svane, MD, PhD, a professor of clinical cancer immune therapy at the University of Copenhagen, and director of National Center for Cancer Immune Therapy at Herlev and Gentofte Hospital, highlighted TILs’ clinical responses when checkpoint inhibitors fail in melanoma during a presentation during the American Association for Cancer Research (AACR) Annual Meeting 2021 held virtually in May.1

READ THE ORIGINAL FULL ARTICLE